Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • Roche
  • Parkinson Study Group
  • CHDI Foundation
  • ACADIA Pharmaceuticals
  • National Institutes of Health
  • Teva Pharmaceutical Industries
  • Acorda Therapeutics
  • National Institute of Neurological Disorders and Stroke
  • St. Jude Medical
  • School of Public Health, University of California, Berkeley
  • Novartis
  • US WorldMeds
  • Abbott Laboratories
  • Medical University of Silesia in Katowice
  • H. Lundbeck A/S
  • Pfizer
  • International Parkinson and Movement Disorder Society
  • AstraZeneca
  • Sunovion
  • Merck
  • Adamas Pharmaceuticals
  • American Parkinson Disease Association
  • Kyowa Kirin Pharmaceutical Development
  • National Parkinson Foundation
  • AbbVie
  • Kyowa Kirin
  • Michael J. Fox Foundation for Parkinson's Research

This publication has 16 references indexed in Scilit: